Literature DB >> 33429176

Mastoid obliteration with S53P4 bioactive glass after canal wall down mastoidectomy: Preliminary results.

B Król1, K B Cywka2, M B Skarżyńska3, P H Skarżyński4.   

Abstract

BACKGROUND: Bioactive glass (S53P4), abbreviated BG, currently seems to be the best material for reconstructing the posterior wall of the auditory canal and obliterating the postoperative cavity.
PURPOSE: The aim of the study was to report preliminary results of otosurgery involving obliteration of the mastoid cavity after canal wall down mastoidectomy.
METHODS: 11 adult patients who had had a history of chronic otitis media with cholesteatoma in one or both ears and previous canal wall down mastoidectomy. The duration of the follow-up was 6 months, with routine visits after 7 days, then 1, 3, and 6 months after surgery. The patient's medical history, noting other diseases potentially affecting the healing process, was analyzed. Healing, audiometric results, reduction of the volume of the cavity after surgery, and reduction of bacterial flora growth were assessed.
RESULTS: There was not worsening in the audiological evaluation. Healing period was uneventful. There was a reduction in volume of the postoperative cavity, no development of pathological flora, and no recurrence of cholesteatoma.
CONCLUSION: Obliteration of the mastoid process with S53P4 bioactive glass is a safe and effective method of treatment. Such a procedure should be considered as a treatment for patients after canal wall down surgery (CWD).
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Canal wall down mastoidectomy; Cholesteatoma; Mastoid obliteration; Otosurgery; S53P4 bioactive glass

Year:  2021        PMID: 33429176     DOI: 10.1016/j.amjoto.2020.102895

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  6 in total

1.  Antibiotics in mastoid and epitympanic obliteration with S53P4 bioactive glass: A retrospective study.

Authors:  Lauranne Alciato; Daniele Bernardeschi; Valérie Pourcher; Naira Mkrtchyan; Frédéric Tankéré; Olivier Sterkers; Ghizlène Lahlou
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-09-14

2.  Post-operative healing and long-term stability after mastoid cavity reconstruction using the middle temporal artery and inferior musculoperiosteal flaps.

Authors:  Arthur Dexian Tan; Jia Hui Ng; David Yong-Ming Low; Heng Wai Yuen
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-15       Impact factor: 2.503

3.  Implantation of the Bonebridge BCI 602 after Mastoid Obliteration with S53P4 Bioactive Glass: A Safe Method of Treating Difficult Anatomical Conditions-Preliminary Results.

Authors:  Bartłomiej Król; Katarzyna Beata Cywka; Magdalena Beata Skarżyńska; Piotr Henryk Skarżyński
Journal:  Life (Basel)       Date:  2021-04-22

4.  Self-Rated Benefits of Auditory Performance after Bonebridge Implantation in Patients with Conductive or Mixed Hearing Loss, or Single-Sided Deafness.

Authors:  Anna Ratuszniak; Piotr H Skarzynski; Elżbieta Gos; Henryk Skarzynski
Journal:  Life (Basel)       Date:  2022-01-18

5.  Postoperative surgical site infection in cholesteatoma surgery with and without mastoid obliteration, what can we learn?

Authors:  F L J Cals; H F E van der Toom; R M Metselaar; A van Linge; M P van der Schroeff; R J Pauw
Journal:  J Otol       Date:  2021-10-29

6.  Evaluation of the Bonebridge BCI 602 active bone conductive implant in adults: efficacy and stability of audiological, surgical, and functional outcomes.

Authors:  Katarzyna B Cywka; Piotr H Skarzynski; Bartlomiej Krol; Stavros Hatzopoulos; Henryk Skarzynski
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-19       Impact factor: 3.236

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.